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Definitions
ajor Depressive Disorder (MDD) is a prevalent
illness that is frequently associated with significant disabil-
ity, morbidity, and mortality. Results from the 2003
National Comorbidity Replication study found that the
lifetime prevalence of MDD among American adults is
16.2%, ranking it among the most common and costly
medical illnesses.
1 Despite the development and availabil-
ity of numerous treatment options for MDD,studies have
shown that antidepressant monotherapy yields only mod-
est rates of response and remission.For example,a meta-
analysis
2 of all double-blind placebo-controlled studies of
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Major Depressive Disorder (MDD) is a prevalent illness that is frequently associated with significant disability, morbid-
ity, and mortality. Despite the development and availability of numerous treatment options for MDD, studies have shown
that antidepressant monotherapy yields only modest rates of response and remission. Clearly, there is an urgent need to
develop more effective treatment strategies for patients with MDD. One possible approach towards the development of
novel pharmacotherapeutic strategies for MDD involves identifying subpopulations of depressed patients who are more
likely to experience the benefits of a given (existing) treatment versus placebo, or versus a second treatment. Attempts
have been made to identify such “subpopulations,” specifically by testing whether a given biological or clinical marker
also serves as a moderator, mediator (correlate), or predictor of clinical improvement following the treatment of MDD
with standard, first-line antidepressants. In the following article, we will attempt to summarize the literature focusing
on several major areas (“leads”) where preliminary evidence exists regarding clinical and biologic moderators, media-
tors, and predictors of symptom improvement in MDD. Such clinical leads will include the presence of hopelessness, anx-
ious symptoms, or medical comorbidity. Biologic leads will include gene polymorphisms, brain metabolism, quantita-
tive electroencephalography, loudness dependence of auditory evoked potentials, and functional brain asymmetry.
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rates of 53% for antidepressants and 36% for placebo
(absolute difference in response rate of 16.8%).Similarly,
Petersen et al
3 report remission rates as low as 20% to
23% following each successive treatment among patients
with MDD enrolled in one of two academically affiliated,
depression-specialty clinics.In fact,only about 50% of all
patients enrolled ultimately achieved full remission of their
depression.Similarly,only about one in three patients with
MDD experienced a remission of their depression follow-
ing treatment with the selective serotonin reuptake
inhibitor (SSRI) citalopram during the first level of the
large,multicenter,Sequenced Treatment Alternatives to
Relieve Depression (STAR*D) trial.
4 Clearly,there is an
urgent need to develop safer,better-tolerated,and more
effective treatments for MDD.
There are three major “paths”towards the development
of novel pharmacotherapeutic strategies for MDD (Table
I).
5The first approach involves developing new antidepres-
sants to be used as monotherapy. A second approach
involves combining pharmacologic agents,including estab-
lished treatments (ie,established antidepressants),exist-
ing but not established agents,and new or novel agents.
Finally,a third approach involves identifying subpopula-
tions of depressed patients who are more likely to expe-
rience the benefits of a given (existing) treatment versus
placebo, or versus a second treatment.Attempts have
been made to identify such “subpopulations,”specifically
by testing whether a given biological clinical marker also
serves as a moderator,mediator (correlate),or predictor
of clinical improvement following the treatment of MDD
with standard,first-line antidepressants.A predictor of
treatment (efficacy) outcome can involve factors
(whether clinical or biologic),the presence or magnitude
of which influences the likelihood of a particular out-
come occurring during treatment.Efficacy outcomes in
MDD commonly include either the resolution of depres-
sive symptoms during treatment (the magnitude of
reduction in depressive symptoms), the rapidity of
response (the time course of symptom reduction), the
attainment of a treatment response,or the attainment of
symptom remission.
Differential predictors or moderators of efficacy outcome
are a special subcategory of outcome predictors.
Moderators of outcome involve factors (clinical or bio-
logic), the presence or magnitude of which at baseline
(immediately before treatment is initiated) influences the
relative likelihood of a particular outcome occurring fol-
lowing treatment with one versus another agent.Thus,
moderators of response can help predict differential effi-
cacy between two or more treatments for MDD (for
example,patients who present with a given moderator
are more likely to respond to treatment with one antide-
pressant versus another than patients who do not present
with that given moderator).
Mediators of efficacy outcome (sometimes also referred
to as correlates) are measurable changes (usually bio-
logic) that occur during treatment and correlate with
treatment outcome.These changes can either precede (in
which case they may also predict outcome—“predictive
mediators”),or temporally coincide with treatment out-
come (“simple mediators”). Differential mediators of
outcome are also possible (changes that predict or corre-
late with an event following treatment with one agent but
not another).Figure 1 provides an overview regarding
the combinations pertaining to mediators,moderators,
and predictors of efficacy outcome in MDD.Table II out-
lines potential clinical,scientific,and treatment-develop-
ment implications that may derive by identifying media-
tors,moderators,and predictors of efficacy outcome in
MDD.
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Selected abbreviations and acronyms
5-HT serotonin
DSM Diagnostic and Statistical Manual of Mental
Disorders
EEG electroencephalogram
HDRS Hamilton Depression Rating Scale
LDAEP loudness dependence of auditory evoked poten-
tials
MAOI monoamine oxidase inhibitor
MDD Major Depressive Disorder
SSRI selective serotonin reuptake inhibitor
STAR*D Sequenced Alternatives to Relieve Depression
TCA tricyclic antidepressant
• Develop new agents as monotherapy
• Combine two or more pharmacologic treatments
o Two or more existing or established agents
o A combination of existing, established, and new agents
• Identify subpopulations of MDD patients who are more likely to 
experience the benefits of a given treatment
o Biological markers
o Clinical markers
Table I. Common pathways towards the development of more effective
pharmacologic strategies for Major Depressive Disorder (MDD).In the following paragraphs,we will attempt to summa-
rize the literature focusing on several major areas
(“leads”) where preliminary evidence exists regarding
clinical and biologic moderators,mediators,and predic-
tors of symptom improvement in MDD.In the first sec-
tion,we will focus on clinical variables while,in the sec-
ond section,on biological variables.
Clinical factors
To date,the overwhelming majority of published studies
focusing on identifying predictors of response during the
acute-phase of treatment of MDD involve the SSRIs.These
studies focus on examining the role of illness characteris-
tics (ie,depressive subtype) or comorbidity (psychiatric (ie,
axis I),characterologic (axis II),and medical (axis III),and
will be reviewed according to antidepressant class.
SSRI treatment
In general,the presence and/or extent of factors associ-
ated with personality or temperament,including the pres-
ence of a Diagnostic and Statistical Manual of Mental
Disorders (DSM)-defined personality disorder,
6-9 neuroti-
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Figure 1. Schematic depiction of definitions. MDD, major depressive disorder
Clinical or biologic variable found to be 
statistically related to treatment outcome 
(acute phase) in MDD
Fixed or variable?
Variable
Precedes or coincides 
with outcome?
Coincides Precedes
Simple or differential?
Simple
Simple predictive
mediator
Differential predictive
mediator
Simple 
mediator
Differential 
mediator
Differential
Simple or differential?
Simple
Simple predictor Moderator
Differential
Simple or differential?
Simple Differential
Fixed
• Identification of factors which are simple predictors of 
treatment outcome would allow for the stratification of 
patients according to risk for treatment-resistance, which, in 
turn, could lead to the development of tailored approaches 
that would improve overall treatment outcome (ie, choosing 
a more “aggressive” treatment a priori).
• Identification of moderators (ie, differential predictors) of 
treatment outcome may lead to the development of tailored 
treatment approaches (algorithms) for a given subgroup of 
MDD patients that would improve treatment outcome 
(ie, matching treatment with MDD subtype).
• Predictive or nonpredictive mediators (correlates) of treatment 
outcome may provide mechanistic insights into the underlying 
pathophysiology of MDD, thereby helping identify new 
molecular targets for drug development or for defining 
clinically relevant subgroups.
• Predictive or nonpredictive mediators (correlates) of treatment 
outcome may be used in screening for potential new 
antidepressants (for example, selecting pharmacologic agents 
that also result in similar changes in clinical or preclinical 
models).
Table II. Potential clinical, scientific and treatment development applica-
tions of predictors, moderators and mediators of treatment out-
come in Major Depressive Disorder.cism,
10 hypochondriacal concerns,
11 dysfunctional atti-
tudes,
12 or temperamental style
13 do not appear to predict
response to the SSRIs.
In contrast, the presence and or degree of general
14 as
well as specific medical comorbidity, including hyper-
cholesterolemia,
15 greater body weight,
16 other risk fac-
tors for vascular disease,
17,18 hypofolatemia,
18-20 and mag-
netic resonance imaging (MRI) white-matter hyperinten-
sities
18,21,22 consistently appear to predict poorer outcome
during the acute phase of treatment of MDD with the
SSRIs, although other factors, such as the presence of
mild hypothyroidism
23 and anemia,
24 do not.
The presence and severity of several symptoms of
depression have also been linked to poorer prognosis,
including hopelessness,
25 cognitive symptoms of depres-
sion including executive dysfunction,
26 physical symptoms
of depression (somatic symptoms including pain,fatigue,
physical symptoms of anxiety,and gastrointestinal symp-
toms),
27-30 and psychomotor retardation.
27 Early improve-
ment in depressive symptoms appears to also predict bet-
ter outcome during the acute phase of treatment of
MDD with fluoxetine,and vice versa.
31,32
Illness features including greater chronicity,
7,8 atypical
depression,
7 depression with anger attacks,
7 or depression
with comorbid attention deficity-hyperactivity disorder,
33
or insomnia
8,34,35 do not appear to confer a worse progno-
sis.However,greater MDD severity was found to predict
a greater likelihood of attaining remission of depression
following treatment with the SSRI escitalopram than sev-
eral older SSRIs (fluoxetine,sertraline,paroxetine,citalo-
pram) in MDD (moderator).
36
The presence of an anxious MDD subtype (defined using
the ”syndromal” approach as MDD presenting with at
least one comorbid DSM anxiety disorder) was found to
result in poorer outcome during the acute phase of treat-
ment of MDD with fluoxetine
7 but not sertraline.
8 Until
recently,however,several relatively small studies
9,37-40 defin-
ing anxious MDD using the “dimensional” approach
(most commonly defined as a score of 7 or more on the
anxiety-somatization subscale (HDRS-AS)
41 of the
Hamilton Depression Rating Scale (HDRS),
42 and have
not confirmed earlier findings by Fava et al.
7The HDRS-
AS subscale is comprised of the following HDRS items:
psychic anxiety,somatic anxiety,somatic symptoms-gas-
trointestinal,somatic symptoms-general,hypochondriasis,
and insight.Other studies
37,43,44 which employ a scale differ-
ent than the HDRS-AS to define anxious MDD (dimen-
sional approach) have also not confirmed the findings of
the earlier work by Fava et al.
7 However,recently,evidence
stemming from Levels 1 and 2 of STAR*D do suggest sig-
nificantly lower remission rates following the treatment of
MDD with either first-line (citalopram) or second-line
treatment strategies (switching to antidepressants versus
augmentation or combination strategies).
45
Most of the studies described above examining the
potential role of several factors as possible predictors of
outcome following the acute phase of treatment of MDD
with an SSRI share two major limitations: (i) most
involve a relatively small sample size,resulting in limited
statistical power to detect an effect of a factor on treat-
ment outcome;and (ii) most involve analyses conducted
in either univariate or bivariate fashion (ie,simply con-
trolling for overall depression severity at baseline).More
recently,Trivedi et al
4 conducted multivariate analyses in
STAR*D,examining potential predictors of response to
open-label citalopram (up to 60 mg, up to 14 weeks of
treatment) in MDD utilizing a dataset of unprecedented
statistical power (n=2876).Variables examined as poten-
tial predictors of outcome included several demographic
(ie,age,gender,race,sociodemographic variables) and
clinical (age of onset of MDD,duration of episode,the
presence of psychiatric and medical comorbidity) factors.
Participants who were Caucasian,female,employed,or
had higher levels of education or income had higher
chances of success. Longer depressive episodes, more
concurrent psychiatric disorders (especially anxiety dis-
orders and or drug abuse) and general medical disorders,
and lower baseline psychosocial functioning and quality
of life were associated with poorer chances of success.
Treatment with older agents (TCAs and MAOIs)
In general,results of these studies parallel those focusing
on the use of SSRIs in MDD.
While the results of two studies suggest that the presence
of a comorbid personality disorder confers an increased
risk of poor outcome during the treatment of MDD with
the tricyclic antidepressants (TCAs),
46,47 the majority of
studies do not support this relationship.
8,48-55 However,two
studies do report poorer outcome among MDD patients
with than without a comorbid cluster C personality dis-
order during TCA treatment.
53,56
Several studies do not report the presence of neuroticism
to predict antidepressant response following TCA treat-
ment in MDD.
50-52,55The interactions of certain elements
of temperament (novelty seeking,harm avoidance,and
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442reward dependence) were found to help predict response
to TCAs in one,
50 but not a subsequent study.
57
Symptom chronicity was found to result in poor outcome
during treatment of MDD with the TCAs in one,
52 but
not a second study.
8 Finally,specific symptoms including
insomnia
8,35 and suicidal ideation
58 do not appear to pre-
dict response to TCA treatment.However,the presence
of somatic symptoms of depression,
59 elevated cholesterol
levels,
60 but not the presence and/or extent of medical
comorbidity
61 have been linked to lower chances of
responding to the TCA nortriptyline in MDD.
Although earlier studies had suggested that patients with
anxious MDD may respond more poorly to treatment
with the TCAs and/or monamine oxidase inhibitors
(MAOIs),
62-64 a number of studies did not find a signifi-
cant relationship between the presence of an anxious
MDD subtype and poorer outcome following treatment
with an MAOI
65-70 or TCA.
9,38,40,48,65-70 Finally,the presence
of atypical MDD has been shown to predict a greater
likelihood of clinical response to treatment with the
MAOI phenelzine than the TCA imipramine.
69,71
Treatment with newer agents
Only a handful of studies specifically focus on identify-
ing predictors of acute-phase outcome (efficacy) during
the treatment of MDD with newer agents. Nelson and
Cloninger
72 reported the interaction of several tempera-
mental factors,including reward dependence and harm
avoidance, to predict response to the serotonin (5HT-
2–receptor antagonist nefazodone in MDD (n=18).This
was confirmed shortly thereafter using a larger database
(n=1119).
73 However,the predictive power of neuroticism
in the latter study accounted for a trivial 1.1% of the total
variance in outcome,raising questions regarding the clin-
ical relevance of this finding.
Rush et al
43,44,74 did not find the presence of pretreatment
anxiety or insomnia to confer a better or poorer progno-
sis during treatment with the noradrenaline-dopamine
reuptake inhibitor (NDRI) bupropion.However,a more
recent analysis involving 10 randomized, double-blind
clinical trials comparing bupropion with an SSRI for
MDD did reveal a greater likelihood of clinical response
following treatment with an SSRI than bupropion among
patients with anxious MDD (moderator).
75
Sir et al
39 and Davidson et al
76 did not find that the pres-
ence of an anxious subtype of MDD or anxious symp-
toms in MDD had influenced the likelihood of respond-
ing to venlafaxine in MDD, although Silverstone and
Salinas
77 found a slower onset of antidepressant effects
among venlafaxine-treated patients with MDD and
comorbid generalized anxiety disorder (GAD) than
those without comorbid GAD,and patients with anxious
depression,as defined by elevated scores on the HDRS-
AS scale,were significantly less likely to remit following
venlafaxine treatment in Level 2 of STAR*D.
45 However,
postmenopausal women with MDD who were not on
hormone-replacement therapy were found to be much
more likely to attain remission of MDD following treat-
ment with the serotonin-norepinephrine reuptake
inhibitor (SNRI) venlafaxine than an SSRI than either
premenopausal women or postmenopausal women on
hormone replacement therapy in one study.
78
Kornstein et al
79 did not find either age nor gender to
influence efficacy outcome following treatment with the
SNRI duloxetine. Mallinckrodt et al
80 did not find the
presence of a melancholic subtype to influence efficacy
outcome following treatment with duloxetine.However,
greater MDD severity was found to predict a greater
likelihood of attaining remission of depression following
treatment with the SNRI duloxetine than the SSRIs flu-
oxetine and paroxetine in MDD (moderator).
81
Biologic factors
To date,numerous studies have explored several poten-
tial genetic markers of outcome during the acute phase
of treatment of MDD.The majority of these studies stem
from one of two fields: genetics and neurophysiology.
Due to the paucity of reports focusing on non-SSRI
agents,biologic factors will be reviewed according to field
(ie,genetics versus neurophysiology) rather than class (ie,
SSRI versus non-SSRI treatment).
Genetic markers
A number of reports explore various genetic markers as
predictors of clinical response to antidepressants in MDD.
The vast majority of these focus on genes coding for pro-
teins directly involved in the monoaminergic system,
including tryptophan hydroxylase (TPH—the rate-limit-
ing step in serotonin synthesis),the serotonin transporter
(5-HTT),the serotonin 5-HT-2 receptors,the monoamine
oxidase enzyme (MAO),and the catechol-O-methyltrans-
ferase enzyme (COMT).The overwhelming majority of
these studies involve treatment with the SSRIs.
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Three studies suggest that patients with a specific poly-
morphism (A218C) in the gene coding for the TPH
enzyme may respond more poorly to SSRIs than those
without such a polymorphism,
82-84 although this was not
confirmed in three other studies.
85-88 Early on,the results
of some
88-98 but not all
99-103 studies also suggested that
depressed patients with a certain (insertion/deletion)
polymorphism located in the promoter region of the
gene coding for the serotonin transporter (5HTTPR)
have a relatively poorer response to the SSRIs than those
without.Several pooled analyses and meta-analyses have
subsequently confirmed a predictive role for 5HTTPR
genotype with regards to SSRI response in MDD,more
so for Caucasian than Asian patients.
104-106 More recently,
however,Kraft et al
107 and,subsequently,Hu et al
108 did
not find an association between response to the SSRI
citalopram and 5HTTPR genotype among 1914 subjects
who participated in the first level of the STAR*D trial.
This report provides the strongest evidence to date
against a role for variation at this gene as a factor predict-
ing clinical response to the SSRIs.
Similarly,there have been conflicting reports regarding
the role of 5-HT2-receptor genotype as a predictor of
SSRI response.Specifically,two studies have identified a
specific single nucleotide polymorphism (SNP) in the
promoter region of the 5-HT2 receptor (A1438G) that
appears to predict response to the SSRIs in MDD.
91,109
However, this finding was not confirmed in a third
report.
110 More recently,however,McMahon et al
111 con-
ducted an analysis of numerous candidate genes as
potential predictors of response to open-label citalopram
in MDD utilizing the STAR*D level-1 dataset (n=1953).
Of 68 candidate genes investigated,only genetic varia-
tion at the locus coding for the 5-HT2 receptor gene was
found to consistently predict clinical outcome,
111 with dif-
ferences in genotype (comparison of two homozygous
groups) accounting for an 18% difference in the absolute
risk of having no response to treatment.
Relatively fewer studies have focused on genes coding
for proteins not directly related to the monoaminergic
system. Using a STAR*D-based dataset, Perlis et al
112
demonstrated a relationship between the presence of a
variant (KCNK2) in a gene (TREK1) coding for a potas-
sium channel and the likelihood of experiencing symp-
tom improvement following treatment of MDD with the
SSRI citalopram. In a separate study, Paddock et al
113
reported that genetic variation in a kainic acid-type glu-
tamate receptor was associated with response to the anti-
depressant citalopram (marker (rs1954787) in the
GRIK4 gene,which codes for the kainic acid-type gluta-
mate receptor KA1). There is also a STAR*D-based
report suggesting a relationship between the likelihood
of achieving remission of symptoms during treatment
with the SSRI citalopram and genotype at one of the
markers (rs4713916) in the FKBP5 gene,a protein of the
hypothalamic-pituitary adrenal (HPA) system modulat-
ing the glucocorticoid receptor.
114
Other agents
Studies looking at genetic markers as predictors of
response to other antidepressants are few.The results of
one study report 5HTTPR genotype to influence the
likelihood of responding to the tricyclic antidepressant
(TCA) nortriptyline in MDD
115 although this could not
be replicated in a separate study.
99Two separate studies
report 5HTTPR genotype to predict response to the
SNRI venlafaxine,
116 and the 5-HT2 alpha-2 adrenergic
receptor inhibitor mirtazapine.
117 Finally,there is also a
single study examining the role of MAO-A genotype as
a predictor of clinical response to the MAOI moclobe-
mide;no relationship was found.
118
Reports from studies comparing agents of different
classes
Reports examining for genetic predictors of response
from randomized,double-blind clinical trials comparing
two antidepressants of different classes are few.Although
preliminary,such studies can be useful in genetic mark-
ers that may serve as moderators of treatment efficacy.
Joyce et al
119 studied 169 MDD patients randomized to
treatment with either fluoxetine or nortriptyline, and
examined whether 5HTTPR or G-protein beta3-subunit
(C825T) genotype influenced symptom improvement fol-
lowing treatment with either of these two agents. For
patients younger than 25 years of age,the T allele of the
G protein beta3 subunit was associated with a poorer
response to nortriptyline. There was no relationship
between 5HTTPR genotype and response to treatment
with either antidepressant among this age group,nor was
there any relationship between G protein beta3 subunit
genotype status and response to paroxetine. Among
patients 25 years of age or older, however, 5HTTPR
Clinical research
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triptyline.Findings stemming from this report have yet
to be replicated.Similarly,Szegedi et al
120 studied the rela-
tionship between the COMT (val158met) polymorphism
status and antidepressant response following treatment
with paroxetine versus mirtazapine (5-HT2-alpha-2
adrenergic receptor antagonist) in MDD. Patients
homozygous for COMT-met showed a poorer response
to mirtazapine than patients with other genotypes.A sim-
ilar finding was not observed during paroxetine treat-
ment.Preliminary findings from these two trials have yet
to be prospectively confirmed.
Neurophysiology
Brain functioning and metabolism
A number of studies have examined the potential rela-
tionship between functional changes,including changes
in regional blood glucose metabolism as measured by
positron emission tomography (PET), and clinical
response following the treatment of MDD with standard
antidepressants.Mayberg,
121,122 for instance,studied the
relationship between regional metabolic changes in the
central nervous system (CNS) and clinical response fol-
lowing a 6-week trial of the SSRI fluoxetine for MDD.
The results of her work suggest that metabolism in cer-
tain brain areas, as measured by PET, may serve as a
mediator of response to the SSRIs.Specifically,she found
an increase in brain stem and dorsal cortical metabolism
(prefrontal,parietal,anterior cingulate,and posterior cin-
gulate),and a decrease in limbic and striatum metabo-
lism (subgenual cingulate,hippocampus,insula,and pal-
ladium) from week 1 to week 6 of treatment among
fluoxetine responders.Fluoxetine nonresponders did not
demonstrate changes in these areas during the same
treatment period (weeks 1-6).Similarly,Iosifescu et al
123
established a relationship between normalization in mea-
sures of brain bioenergetic metabolism among patients
with SSRI-resistant MDD who experienced symptom
improvement (clinical response) following T3 augmen-
tation of their SSRI treatment regimen.
In a recent work,Mayberg et al
121 reviewed earlier stud-
ies examining the relationship between regional meta-
bolic changes and symptom improvement during the
treatment of MDD with antidepressants,and concluded
that a significant correlation between normalization of
frontal hypometabolism and clinical improvement was
the best-replicated finding.However,a similar relation-
ship (ie,between an increase in frontal metabolism and
symptom improvement) was also reported during
placebo treatment.
121The results of the latter study sug-
gest that such changes,at least as detected by the tech-
nology available at the time,appear to be related to non-
specific (placebo) rather than specific (drug) treatment
effects and,therefore,may not serve as robust differen-
tial treatment mediators.Little et al,
124 for instance,exam-
ined whether there are differences in the relationship
between brain metabolism at baseline (predictor or mod-
erator) and symptom improvement between two antide-
pressants of different class (the NDRI bupropion versus
the SNRI venlafaxine).For the most part,similar find-
ings predicted symptom improvement for both agents
(frontal and left temporal hypometabolism), although
some differences emerged (compared with control sub-
jects,bupropion responders (n = 6) also had cerebellar
hypermetabolism, whereas venlafaxine responders
showed bilateral temporal and basal ganglia hypometab-
olism).This study has yet to be replicated, either with
regards to baseline brain metabolism (ie,moderator of
response),or changes in baseline brain metabolism (ie,
mediator of response).
Quantitative EEG
Quantitative electroencephalography (QEEG) involves
the use of computer software analysis to deconstruct
electroencephalographic (EEG) tracings and quantify
parameters including frequency and amplitudes (tradi-
tional EEG involves manual readings).A relevant mea-
surement generated by the software traditionally
employed by QEEG is called cordance,which involves a
combination of absolute power (the power of a fre-
quency band) and relative power (the percentage of
power in a frequency band compared with the total
power across all frequency bands).
125,126 Cordance of
frontal EEG measurements in the theta band (4 to 8Hz)
has consistently been found to correlate with antidepres-
sant response in MDD.Specifically,the result of several
studies suggest a decrease in theta cordance from pre-
frontal EEG leads during the first week of treatment
with either an SSRI,an SNRI,or a variety of antidepres-
sants,to predict greater symptom improvement follow-
ing 4 to 10 weeks of treatment.
127-129 In contrast, an
increase in prefrontal theta cordance during the first
week of treatment was demonstrated among placebo-
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may serve as a differential (predictive) mediator of
response to antidepressants versus placebo.
130
Interestingly enough,a report by Hunter et al
131 suggests
that the decrease in prefrontal EEG theta cordance dur-
ing the week immediately preceding the initiation of
treatment of MDD with antidepressants (fluoxetine,ven-
lafaxine) or placebo (placebo lead-in period) is related
to the likelihood of responding to antidepressants but not
placebo following 9 weeks of treatment (moderator of
response).Thus,the sum of the evidence reviewed above
suggests a potential role for the change in prefrontal
theta EEG cordance during the first week of treatment
in MDD as a mediator and predictor of response to anti-
depressants but not placebo (differential mediator).
Although the exact physiologic relevance of this proba-
ble treatment mediator is, at present, unclear, several
lines of evidence suggest it may serve as a proxy for
changes in underlying prefrontal cortex metabolism (see
ref 127 for further details).
Loudness dependence of auditory evoked potentials 
Much less is known regarding the potential predictive
ability of other EEG-related biomarkers. Loudness
dependence of auditory evoked potentials (LDAEP) is
one such measurement, derived from EEG recordings
thought to correspond to the primary auditory cortex fol-
lowing the administration of an auditory stimulus.
125 A
“strong” LDAEP suggests that the characteristics of
evoked potentials following an auditory stimulus are
highly dependent on the intensity (loudness) of the audi-
tory stimulus.
134 In contrast,a “weak”LDAEP suggests
that evoked potentials following an auditory stimulus do
not vary much as a function of how loud the sound is.
132
To date,a variety of clinical studies have demonstrated
that patients with “strong”LDAEP at baseline are more
likely to respond to treatment with SSRIs than those
with “weak” LDEAP.
133-137 However, in a small (n=35)
randomized,open-label trial comparing the SSRI citalo-
pram with the norepinephrine reuptake inhibitor (NRI)
reboxetine for MDD, patients with “strong” LDAEP
were more likely to respond to citalopram than reboxe-
tine while patients with “weak” LDAEP were more
likely to response to reboxetine than citalopram
138 (dif-
ferential predictor or moderator of response).Double-
blind,randomized clinical trials involving treatment with
antidepressants of different class (ie,SSRI versus NRI)
which are specifically designed to examine any potential
moderating effects of LDAEP (ie,randomization based
on LDAEP status would also need to occur) have yet to
be conducted.
Brain functional asymmetry (dichotic listening)
Dichotic listening tasks involve auditory stimuli being
presented to both the left and the right ear.Potential dif-
ferences in perception (perceptual asymmetry) are then
used as a proxy for brain functional asymmetry.Bruder
et al
140 first studied the relationship between the presence
of perceptual asymmetry following dichotic listening
tasks at baseline and symptom improvement following
treatment with the TCAs.A left-ear (right hemisphere)
advantage was significantly more common among non-
responders than responders.This was replicated for flu-
oxetine (SSRI) treatment in two different studies
140,141 and
bupropion (NDRI) treatment in a separate study.
142
Conclusion
A number of potential clinical predictors of symptom
improvement during the pharmacologic treatment of
MDD have been identified to date,mostly from studies
focusing on the acute phase of treatment of MDD with
the SSRIs.These include the presence of a greater num-
ber of concurrent psychiatric disorders (especially anxi-
ety disorders),or general medical disorders (ie,cardio-
vascular illness,hypofolatemia).The presence of or more
of these factors should alert clinicians to alter their treat-
ment approach in order to help optimize the chances of
patients recovering from depression.For instance,clini-
cians may chose to initiate therapy with two treatments,
ie,pharmacotherapy and psychotherapy,schedule more
frequent follow-up visits, increase the dose sooner in
treatment nonresponders,or resort to various switching,
augmentation, or combination strategies sooner for
patients who do not experience a sufficient improvement
in symptoms. Several potential clinical mediators of
response have also been identified including the presence
of severe MDD (escitalopram and duloxetine versus
“older” SSRIs), anxious MDD (bupropion versus
SSRIs),atypical MDD (MAOIs versus TCAs),and hor-
monal status among women (venlafaxine versus “older”
SSRIs).However,at the present time,such “leads”are
preliminary and have not been prospectively confirmed
in randomized,double-blind clinical trials.Finally,pre-
Clinical research
446liminary studies have identified a number of putative
“biomarkers,” relating to genetic or neurophysiologic
(particularly quantitative EEG (QEEG)-based measure-
ments as well as measures of prefrontal cortical metabo-
lism),which appear to correlate with symptom improve-
ment during the treatment of MDD with 
standard antidepressants (mediators of response).
Conducting further studies designed to establish reliable,
replicable,and robust biological factors which function
as predictors, mediators, or moderators of clinical
improvement in MDD could benefit the field in several
ways,from enhancing our ability to develop more effec-
tive treatments to improving our ability to choose an
individualized pharmacotherapeutic regimen for patients
with MDD which would result in a more rapid and
robust resolution of depressive symptoms. ❏
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Predictores, moderadores y mediadores
(correlatos) de la evolución del tratamiento
en el trastorno depresivo mayor
El trastorno depresivo mayor (TDM) es una enfer-
medad prevalente que está asociada frecuente-
mente con incapacidad, morbilidad y mortalidad
significativas. A pesar del desarrollo y de la dispo-
nibilidad de numerosas opciones terapéuticas para
el TDM, los estudios han mostrado que la monote-
rapia antidepresiva sólo produce bajas frecuencias
de respuesta y remisión. Es claro que hay una
urgente necesidad de desarrollar estrategias tera-
péuticas más efectivas para los pacientes con TDM.
Una posible aproximación para el desarrollo de
novedosas estrategias farmacoterapéuticas para el
TDM implica identificar subpoblaciones de pacien-
tes depresivos que con mayor probabilidad expe-
rimenten los beneficios de un tratamiento dado
(existente) versus placebo, o versus un segundo tra-
tamiento. Se han realizado intentos para identifi-
car tales “subpoblaciones”, específicamente anali-
zando si un determinado marcador biológico o
clínico también sirve como un moderador, media-
dor (correlato) o predictor de la mejoría clínica en
el tratamiento del TDM con antidepresivos están-
dar de primera línea. En este artículo se intentará
resumir la literatura focalizada en algunas áreas
principales (“pistas”) donde existe evidencia preli-
minar relacionada con moderadores, mediadores y
predictores clínicos y biológicos de mejoría de sín-
tomas en el TDM. Las pistas clínicas incluirán la pre-
sencia de desesperanza, síntomas ansiosos o comor-
bilidad médica. Las pistas biológicas incluirán
polimorfismo genético, metabolismo cerebral, elec-
troencefalografía cuantitativa, dependencia a la
intensidad del volumen de los potenciales evocados
auditivos y asimetría cerebral funcional.
Facteurs prédictifs, modérateurs et média-
teurs (corrélats) des effets thérapeutiques
dans le trouble dépressif majeur
Le trouble dépressif majeur (TDM) est une patholo-
gie prévalente fréquemment associée à une invali-
dité, une morbidité et une mortalité significatives.
Malgré le développement et l’existence de nom-
breux traitements pour le TDM, des études ont mon-
tré que les monothérapies antidépressives ne don-
naient que de modestes taux de réponse et de
rémission. Il devient vraiment urgent de développer
des stratégies thérapeutiques efficaces pour les
patients atteints de TDM. Une approche éventuelle
pour un tel développement serait d’identifier des
sous-populations de patients déprimés plus suscep-
tibles de bénéficier d’un traitement donné (existant)
versus placebo ou versus un second traitement. Des
tentatives ont été menées afin d’identifier de telles
« sous-populations », en vérifiant en particulier si un
marqueur biologique ou clinique donné pouvaitt
aussi servir de modérateur, médiateur (corrélat) ou
prédicteur de l’amélioration clinique consécutive au
traitement du TDM avec des antidépresseurs stan-
dard de première intention. Dans cet article, nous
allons essayer de résumer la littérature dirigée vers
plusieurs axes importants (« directeurs ») et pour les-
quels il existe des arguments préliminaires en ce qui
concerne les prédicteurs, médiateurs et modérateurs
cliniques et biologiques de l’amélioration des symp-
tômes du TDM. Ces symptômes cliniques « directeurs
» incluront les symptômes de désespoir,d’anxiété ou
de comorbidité médicale. Le polymorphisme géné-
tique, le métabolisme cérébral, l’électroencéphalo-
graphie quantitative, la dépendance à l’intensité du
son des potentiels évoqués auditifs et l’asymétrie
cérébrale fonctionnelle feront partie des critères bio-
logiques directeurs exposés.Clinical research
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